Predictive factors of disability in patients with leprosy

Abstracts

OBJETIVO:Analisar os fatores preditivos na evolução do grau de incapacidade em pacientes com hanseníase. MÉTODOS:Foram analisados dados de coorte retrospectiva, que acompanhou 595 pacientes com incapacidades, registrados em uma unidade de saúde de Belo Horizonte (MG), de 1993 a 2003. Informações sociodemográficas e clínicas dos pacientes foram coletadas dos respectivos prontuários. Comparou-se o grau de incapacidade na admissão e no final do tratamento por meio do teste de homogeneidade marginal. Para identificar os fatores associados à evolução do grau de incapacidade foram utilizadas as análises univariada (teste qui-quadrado de tendência linear) e multivariada pelo algoritmo Chi-square Automatic Interaction Detector. RESULTADOS:Dos casos com registro de grau de incapacidade na admissão e na alta, observou-se que 43,2% que tinham grau 1 na primeira avaliação evoluíram para grau 0. Dos que apresentavam grau 2, 21,3% passaram a ter grau 0 e 20% passaram a grau 1. Na análise univariada as variáveis que se mostraram estatisticamente associadas à evolução no grau de incapacidade foram: neurite, tempo até a ocorrência de neurite, número de nervos acometidos, tipo de tratamento fisioterápico e maior dose de prednisona. Na análise multivariada, o principal fator que se associou à evolução do grau de incapacidade foi o grau de incapacidade na admissão. CONCLUSÕES:Os resultados mostraram a importância do diagnóstico precoce de neuropatia, assim como da eficiente associação das intervenções medicamentosas e não-medicamentosas por meio das técnicas de prevenção de incapacidade e dosagens adequadas de corticoterapia.

Hanseníase; Hanseníase; Estatísticas de Seqüelas e Incapacidade; Fatores de Risco; Evolução Clínica

ORIGINAL ARTICLES

Predictive factors of disability in patients with leprosy

Factores predictivos de incapacidades en pacientes con hanseníasis

Soraya Diniz Gonçalves^I;Rosana Ferreira Sampaio^II;Carlos Maurício de Figueiredo Antunes^II

^IPontifícia da Universidade Católica de Minas Gerais. Belo Horizonte, MG, Brasil

^IIUniversidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil

^{Correspondence}

ABSTRACT

OBJECTIVE:To analyze predictive factors in the progression of the disability grade in patients with leprosy.

METHODS:A retrospective cohort study followed up 595 patients with disability registered at a healthcare unit in the city of Belo Horizonte (Southeastern Brazil) from 1993 to 2003. Patients' sociodemographic and clinical information was collected from the respective medical records. Comparisons were made between the disability grade upon admission and at the end of treatment using a marginal homogeneity test. To determine factors associated with progression in the disability grade, univariate analysis (linear trend chi-square test) was employed, as well as multivariate analysis by means of the algorithm Chi-square Automatic Interaction Detector.

RESULTS:Among the cases in which the disability grade was recorded upon admission and upon discharge, 43.2% of the patients who had grade 1 in the first assessment progressed to grade 0. Among those who began with grade 2, 21.3% progressed to grade 0 and 20% progressed to grade 1. In the univariate analysis, the variables that proved to be statistically associated with progression in the disability grade were: neuritis, time elapsed until the occurrence of neuritis, number of damaged nerves, type of physiotherapy treatment and higher dose of prednisone. In the multivariate analysis, the main factor associated with the progression of disability was the disability grade upon admission.

CONCLUSIONS:The results showed the importance of an early diagnosis of neuropathy as well as the efficient association of pharmacological and non-pharmacological treatment, through disability prevention techniques and adequate doses of steroid.

Descriptors: Leprosy, complications. Leprosy, prevention & control. Statistics on Sequelae and Disability. Risk Factors. Clinical Evolution.

RESUMEN

OBJETIVO: Analizar los factores predictivos en la evolución del grado de incapacidad en pacientes con hanseníasis.

MÉTODOS: Fueron analizados datos de cohorte retrospectiva, que acompañó 595 pacientes con incapacidades, registrados en una unidad de salud de Belo Horizonte (Sureste de Brasil), de 1993 a 2003. Informaciones sociodemográficas y clínicas de los pacientes fueron colectadas de los respectivos prontuarios. Se comparó el grado de incapacidad en la admisión y en el final del tratamiento por medio de la prueba de homogeneidad marginal. Para identificar los factores asociados a la evolución del grado de incapacidad fueron utilizados los análisis univariado (prueba chi-cuadrado de tendencia linear) y multivariado por el algoritmo Chi-square Automatic Interaction Detector.

RESULTADOS: De los casos con registro de grado de incapacidad en la admisión y en el alta, se observó que 43,2% que tenían grado 1 en la primera evaluación evolucionaron para el grado 0. De los que presentaban grado 2, 21,3% pasaron a tener grado 0 y 20% pasaron a grado 1. En el análisis univariado las variables que se mostraron estadísticamente asociados a la evolución en el grado de incapacidad fueron: neuritis, tiempo hasta la ocurrencia de la neuritis, número de nervios afectados, tipo de tratamiento fisioterapéutico y mayor dosis de prednisona. En el análisis multivariado, el principal factor que se asoció a la evolución del grado de incapacidad fue el grado de incapacidad en la admisión.

CONCLUSIONES: Los resultados mostraron la importancia del diagnóstico precoz de neuropatía, así como de la eficiente asociación de las intervenciones medicamentosas y no medicamentosas por medio de las técnicas de prevención de incapacidad y dosis adecuadas de corticoterapia.

Descriptores: Lepra, complicaciones. Lepra, prevención & control. Estadísticas de Secuelas y Discapacidad. Factores de Riesgo. Evolución Clínica.

INTRODUCTION

Publications on the number of people who present disabilities due to leprosy are scarce. Estimates suggest that approximately two to three million individuals have some degree of physical damage as a result of the disease.^15,18,19 Moreover, studies show that around 20% of patients with leprosy or treated for leprosy may present physical disabilities and psychosocial restrictions, and they often need some kind of intervention in rehabilitation and/or continuity of medical care.⁶ In Brazil, approximately 23% of patients with leprosy present some kind of disability after discharge.^ª

Nowadays, the prevention of physical deficiencies and disabilities resulting from the disease is performed by means of early diagnosis and treatment, and also through the monitoring and adequate management of episodes of neuropathy and leprosy reactions. These reactions are manifestations of the patient's immune system in the presence of the bacillus, and they cause the exacerbation and emergence of new skin lesions, systemic inflammatory processes that may or may not be associated with neuropathy.^5,7,8,19

Monitoring by means of systematic neurological examination enables early diagnosis and intervention in neural impairment, which reduces the patient's chances of developing disabilities. ^1,b The nerve can be recovered with the use of steroid in doses that are adequate to the patient's weight and to the intensity of the neural damage, together with immobilization procedures of the damaged segment and specific therapeutic exercises.^c Early diagnosis and the adequate treatment of reactions and neuritises are fundamental to avoid or reduce complications (deformities and disabilities), lowering rehabilitation costs and having a positive impact on the individuals' functionality and quality of life.

The present study aimed to analyze predictive factors in the progression of the disability grade in patients with leprosy.

METHODS

The study was based on data from a retrospective cohort composed of 595 patients registered at a healthcare unit in the city of Belo Horizonte (state of Minas Gerais, Brazil) between 1993 and 2003. These patients' diagnosis of leprosy was made by a dermatologist of the unit, according to the criteria of the National Program for Leprosy Control.^ª Patients were treated with polychemotherapy, attended physiotherapy sessions with neurological assessments at the onset, during and at the end of treatment, and were discharged in a state of pharmacological cure. Neurological assessments and evaluations of the disability grade were performed by a physiotherapist, using the national protocol for simplified neurological assessment and the disability grading system.^11,ª

Sociodemographic and clinical information was collected from the medical records: sex, age, region of origin, profession, clinical form, occurrence of neuropathy, reactions, physiotherapeutic monitoring, bacteriological index upon admission, number of damaged nerves at the beginning of treatment, medical prescription for the use and initial dosage of prednisone, time elapsed since the onset of treatment with polychemotherapy, disability grade at the beginning and end of treatment.

The association between the predictive factors and progression of the disability grade was performed by means of the marginal homogeneity test, comparing the disability grade upon admission and upon discharge (termination of drug therapy). When a positive dynamics was verified in the progression of the disability grade, univariate analysis was carried out through the linear trend chi-square test. The response variable was defined as progression in the disability grade, which is a result of the comparison of the disability grade upon admission and upon discharge, coded in three categories (the patient's health condition "improved", "remained constant", "deteriorated").

Then, multivariate analysis by means of the decision tree was performed, using the algorithm Chi-square Automatic Interaction Detector (CHAID). This analysis employs classification rules based on a decision tree, allowing to identify homogeneous groups of patients from the systematic comparison of their characteristics in order to establish the relationship between explanatory variables and one single response variable. To achieve this, adjustments through successive divisions into the set of data were made, aiming to make the subsets become more and more homogeneous in relation to the response variable. The division process was repeated until none of the selected variables showed significant influence on the division or when the size of the subset was very small.³

In the analysis using CHAID, all the sociodemographic and clinical variables were initially included in the regression tree. To exclude variables from the model, that is, as the criterion to stop the tree's growth, the p value of the linear trend chi-square statistics was adopted, with Bonferroni adjustment (p<0,05).

The cross-validation procedure was applied to generate sub-samples of the analyzed data. To each sub-sample, a different tree was produced. In this way, the model can be validated if all sub-samples converge to similar trees. Ten sub-samples were used to validate the results by means of the cross-validation procedure. Final model adjustment was evaluated through risk estimation, considering the difference between the expected value and the value observed by the model.³

For the statistical analyses, SPSS 12.0 was used.

The study was approved by the Ethics Committee of Universidade Federal de Minas Gerais.

RESULTS

Of the 595 studied patients, 317 were males (53.3%) and 278 were females (46.7%). Mean age was 42±16.5 years. Concerning occupation, 89 (21.8%) worked in the service and commerce sectors, 81 (19.9%) worked in the industrial goods and services sector, 71 (17.4%) were housewives, 46 (11.3%) were students, 34 (8.3%) were retired and 87 (21.3%) were classified as "others".

Table 1 presents the patients' clinical characteristics. It can be seen that 53% of the sample had neuritis, 19% had leprosy reactions and 26% presented a positive bacteriological index. Neuropathies were diagnosed according to alterations to the neurological examination, based on pain and neural thickening, sensitive and/or motor deficit. As for the treatment received, 14.6% of the sample received physiotherapeutic monitoring with exercises and instructions; 66.3% needed instructions only; 12.5% were advised to use insoles, ankle-foot orthosis with dorsiflexion assist and/or functional orthoses for the hands; and 6.5%, immobilizations.

The maximum period of time elapsed until the occurrence of neuritis was 24 months; a little less than half of the cases (48%) occurred up to the 12^th month of treatment.

Among the cohort's patients, 456 (76.6%) had records about the disability grade upon admission and upon discharge (termination of drug therapy). The other patients had no records of the disability grade upon admission and/or discharge.

It was observed that 43.2% of the patients who had grade 1 in the first assessment progressed to grade 0 (Table 2). Among those who began with grade 2, 21.3% progressed to grade 0 and 20% progressed to grade 1 (p<0.001), which showed a positive dynamics in the disability grading.

The sociodemographic variables (occupation, sex, age and region of origin) did not associate with the progression of the disability grade.

Univariate analysis through the linear trend chi-square test (g.l.=1) showed that the variables that proved to be associated with the improvement in the progression of the disability grade were: occurrence of neuritis (p=0.028), time elapsed until the occurrence of neuritis below 15 months (p=0.006), more than three damaged nerves (p=0.001), exercises and instructions as the type of physiotherapy treatment (p<0.001) and dose of prednisone over 60 mg (p<0.001).

The analysis of the decision tree by means of the algorithm CHAID is represented in Figures 1 and 2. The factors associated with the progression of the disability grade were: disability grade upon admission, type of physiotherapy treatment, age, higher dose of prednisone, number of damaged nerves and type of reactional state.

Disability grade upon admission was the main predictive factor of disability progression. Among the patients who had grade 0 of disability upon admission and received "other physiotherapy treatments", 67% maintained the same disability grade and the state of 33% deteriorated. For those who had grade 0 of disability upon admission and received as physiotherapy treatment "exercises, instructions or immobilizations", took "20 to 30 mg of prednisone", "60 mg or more" or "did not take prednisone", the influence of age could be observed. Thus, all patients with age below 61 years (100%) remained constant in their disability grade. Among those with ages above 61 years, there was deterioration in one case, which represents a percentage of approximately 6%.

Observing the patients who started the study with grade 1 or 2 and who used as physiotherapy treatment "exercises and instructions" or "just exercises" (cases on the right side of the tree, Figure 2), there was improvement in almost 56% of the cases, of which none deteriorated. Patients in whom "immobilization" or "others" were employed as form of physiotherapy treatment, who were younger than 54 years and who had less than six damaged nerves at the beginning of treatment improved their state in more than half of the cases (54%). However, among those who had these same characteristics and more than six damaged nerves, none improved their state - the disability grade they had at the beginning of treatment remained the same.

For patients with grades 1 and 2 who needed "immobilization" or "others" as treatment and were older than 54 years, the type of reactional state was an important factor: 25% of those who had type I reaction improved their state and in 100% of the cases, patients who had type II reactions remained constant.

As for the physiotherapy treatment, of the 163 patients who started treatment classified as grade 1 or 2, 69 obtained an improvement in the disability grading and only one deteriorated. Of these 69, 54 needed exercises and instructions and 15 needed immobilization, of whom 14 were younger than 54 years and had less than six damaged nerves.

The model generated by the decision tree presented good adjustment. Its risk estimation was just 0.13 (standard error=0.02) and it proved to be a stable model, considering that the risk estimated by cross-validation was very close to the final model (risk-0.17; SE=0.02).

DISCUSSION

Neuropathies occurred in more than half of the sample. Despite the high risk of deformities in the comparison between the disability grade upon admission and upon discharge, an important improvement was perceived, with predominance of progression to grade 0 of disability. The majority of patients improved their state or remained in the same disability grade they were in when the diagnosis was made. The results of the present study showed that only 10% remained in grade 2 of disability after treatment, with the consequent improvement in the epidemiological indicator, which moved from high to medium. These findings are different from those of Deepak (2003),⁶ who found high prevalence of grade 2 disabilities in world-wide data. He also found that this prevalence can vary from 17% to 50% after discharge.

The reduction in the prevalence of grades 1 and 2 of disability found in the present study may be related to the frequency of neurological assessments, which were performed every four months or in an even shorter interval of time. Frequent assessments contribute to the early diagnosis of neural damage, as well as to monitor the evolution of this neurological presentation, subsidizing both the pharmacological treatment, with the use of prednisone, and the physiotherapy treatment. Another important factor was the prescription of prednisone in adequate dosages, according to the results of the neurological assessment that was employed to aid the management of these drugs. The clinical rigor used in patients' grading was also important, with a longer follow-up. These factors increased the chances of diagnosing neuritis in the period of the highest incidence of the presentation, which is up to the 12^th month. Besides, frequent neurological examinations are important, due to the high occurrence of silent neuritis, which should be constantly investigated. ^4,16,17

Research has shown the efficiency of the treatment with polychemotherapy, as the deformities rate decrease among new cases. This treatment protocol has enabled early diagnosis and systematized follow-up^2,18,20 associated with neural monitoring and interventions aiming at adequate diagnosis and treatment (pharmacological and non-pharmacological) of episodes of neuropathy, associated or not with reactional states.^8,19 These measures have produced good results, such as the one found in the present study: in only 1.3% of the cases there was a deterioration of the neurological presentation.

Selvaraj et al (1998),¹² in an assessment carried out in India with 1,262 leprosy patients, showed that the individual who is older than 45 years, has more than three thickened nerves and plantar anesthesia had an almost 20 times higher probability of developing new disabilities during and after treatment. According to these authors, the local health team was afraid and there were no protocols to the utilization of the steroid. The authors argued that this aspect is relevant to the bad progression of the deformities.

There are evidences of associations between age, sex, clinical form, number of damaged nerves at the beginning of treatment, bacteriological index and adopted treatment in the determination of the probability of occurrence of disabilities. ^{9,10,12,13,14} In the present study, among all the statistically significant variables, it was possible to verify the importance of the use of prednisone, as well as the type of adopted physiotherapy treatment, contributing to the patients' good evolution. The results showed other variables that predicted a good progression of the disability grade, such as: presence of neuritis, utilization of a dosage of prednisone above 60 mg, more than three damaged nerves upon admission and less than 15 months to the occurrence of neuritis. We expected that the set of variables mentioned above would predict a deterioration of the disability grade; however, they predicted the improvement. This confirms that the diagnosis was made in an early stage of the process and the treatment was instituted in an efficient way, as, generally speaking, the progression was satisfactory to the major part of the sample.

It seems to be a consensus that the absence of an early diagnosis of neuropathies, the fear and the non-adoption of protocols in the use of prednisone are frequent findings that determine, many times, deficiencies and disabilities.^5,7,12,13,19 In the present study, there was a 15% improvement in the disability grade since admission, possibly due to adequate pharmacological interventions (steroid) and appropriate non-pharmacological actions (disability prevention techniques) carried out by the health team.

According to some studies,^10,13 neural damages occur mainly before the diagnosis and the incidence of new damages after the diagnosis is low. A research study conducted in India showed the incidence of new disabilities after treatment with polychemotherapy: 0.681/1000 people/year during treatment with polychemotherapy. ¹³ Similar results were found in the present study, with a very low percentage of deterioration.

Investigations that analyze the disability prevention techniques adopted in the follow-up of the leprosy patient are scarce. In the majority of them, the techniques are described and recommended, without any evaluation of their efficacy and of their potential to predict the progression of the neurological presentation.² We verified the importance of the association between pharmacological and non-pharmacological treatments for a successful prevention of deformities and consequent disabilities of the leprosy patient. The results confirmed the importance of an early diagnosis both of the disease and of the neuropathies that occur during treatment. Furthermore, the results showed that the disability prevention techniques have a clinical impact and predict the good progression of the neurological presentation.

The analysis with the CHAID algorithm enabled the development of a decision rule directed at the individual and not at a group of participants, with direct application to the clinical practice of professionals who deal with leprosy. The selected predicting variables represent clinical parameters frequently observed in the daily routine of an outpatient clinic, enabling the individualized application of the results. Disability grading upon admission was the main variable that predicted the progression of the disability grade. Therefore, it was important in the prevention of neural damages, strengthening the need of an early diagnosis. The evolution of the patient's clinical presentation depends on how he was admitted for treatment. Thus, the improvement, deterioration or maintenance of the patient's clinical presentation after the pharmacological and physiotherapy interventions are associated with or reflect the patient's initial presentation. This aspect is important in rehabilitation, because the focus of the treatment is not on curing the disease; rather, it is on developing the patients' functional capacity to the maximum extent and avoiding that new dysfunctions occur. Other variables also determine the progression of the disability grade: physiotherapy interventions, age and the type of reactional state give an outstanding contribution, influencing on the progression of the disability grade.

The present study presents limitations due to the fact that it was conducted with secondary data. It was not possible to collect data on co-morbidities, patients' body weight and number of neurological assessments performed on the patient.

In short, non-pharmacological interventions contribute to the good evolution of the disability grade in individuals with leprosy. Utilization of the disability prevention techniques as a variable showed the need to carry out these procedures routinely in the services that work with such patients, including frequent neural monitoring, instructions/health education, exercises and orthoses. The association between early diagnosis of neuropathies, use of adequate dosages of steroid and specific techniques for the prevention of disabilities may reduce the prevalence of deformities.

REFERENCES

Received: 8/28/2008

Accepted: 9/7/2008

Article based on the doctoral dissertation authored by Gonçalves SD, presented to the Post-Graduation Program in Health Sciences: Infectology and Tropical Medicine of Universidade Federal de Minas Gerais, in 2006.

• 1. Agrawal A, Pandit L, Dalal M, Shetty JP. Neurological Manifestations of Hansen's disease and their management. Clin Neurol Neurosurg. 2005;107(6):445-54. DOI:10.1016/j.clineuro.2005.03.007
• 2. Brandsma W. Basic nerve function assessment in leprosy patients. Lepr Rev. 1981; 52(2):161-70.
• 3. Breiman LJH, Friedman RA, Stone CJ. Classification and regression Trees. Belmont: Chapman & Hall; 1984.
• 4. Charosky CB, Gatti JC, Cardama JE. Neuropathies in Hansen's disease. Int J Lepr Other Mycobact Dis. 1983;51(4):576-86.
• 5. Croft, RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev. 1999;70(2):140-59.
• 6. Deepak S. Answering the rehabilitation needs of leprosy affected persons in integrated setting through primary health care services and community based rehabilitation. Indian J Lepr. 2003;75(2):127-42.
• 7. Zhang G, Li W, Yan L, Yang Z, Chen X, Zheng T, et al. An epidemiological survey of deformities and disabilities among 14.257 cases of leprosy in 11 counties. Lepr Rev. 1993;64(2):143-9.
• 8. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 14 years experience from North India. Int J Lepr Other Mycobact Dis. 2004;72(2):125-33.
• 9. Meima A, Saunderson PR, Gebre S, Desta K, van Oortmarssen GJ, Habbema JD. Factors associated with impairments in new leprosy patients: the AMFES cohort. Lepr Rev. 1999; 70(2):189-203
• 10. Meima A, Saunderson PR, Gebre S, Desta K, Habbema JD. Dynamics of impairment during and after treatment: the AMFES cohort. Lepr Rev. 2001;72(2):158-70.
• 11. Nienhuis WA, van Brakel WH, Butlin CR, van der Werf TS. Measuring impairment caused by leprosy: Inter-tester reliability of the WHO disability grading system. Lepr Rev. 2004;75(3):221-32.
• 12. Selvaraj G, Prabakar N, Muliyil J, Martin G. Incidence of disabilities among multi-bacillary cases after initiation of multidrug therapy and factors associated with the risk of developing disabilities. Indian J Lepr. 1998;70(Supl):11-6.
• 13. Sharma P, Kar HK, Beena KR, Kaur H, Narayan R. Disabilities in multibacilary leprosy patients: before, during and after multidrug therapy. Indian J Lepr. 1996;68(2):127-36.
• 14. Smith WC, Antin US, Patole AR. Disability in leprosy: a relevant measurement of progress in leprosy control. Lepr Rev. 1980;51(2):155-66.
• 15. Spierings E, De Boer T, Zulianello L, Ottenhoff TH. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol. 2000;78(4):349-55. DOI:10.1046/j.1440-1711.2000.00939.x
• 16. van Brakel WH. Detecting peripheral nerve damage in the field our tools in 2000 and beyond. Indian J Lepr. 2000;72(1):47-64.
• 17. Van Brakel WH. Peripheral neuropathy in leprosy and its consequences. Lepr Rev. 2000;71(Supl):S146-53.
• 18. Leprosy disabilities: magnitude of the problem. Wkly Epidemiol Rec. 1995;70(38): 269-76.
• 19. Willcox ML. The impact of multiple drug therapy on leprosy disabilities. Lepr Rev. 1997;68(4):350-66.
• 20. Young SK, Taylor GM, Jain S, Suneetha LM, Suneetha S, Lockwood DN, et al. Microsatellite mapping of Mycobacterium leprae populations in infected humans. J Clin Microbiol. 2004;42(11):4931-46. DOI:10.1128/JCM.42.11.4931-4936.2004

a

Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Gestão de Políticas Estratégicas. Relatório de atividades da área técnica de dermatologia sanitária. Brasília; 1999.

b

Ministério da Saúde. Manual de prevenção de incapacidades. Brasília; 2001.

c

Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica Guia para controle da hanseníase. Brasília; 2002. (Cadernos de Atenção Básica, 10).

Publication Dates

• Publication in this collection
  10 Mar 2009
• Date of issue
  Apr 2009

History

• Accepted
  07 Sept 2008
• Received
  28 Aug 2008